𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis

✍ Scribed by Alexander M. Walker; Donnie Funch; Nancy A. Dreyer; Keith G. Tolman; Joel M. Kremer; Graciela S. Alarcón; Randall G. Lee; Michael E. Weinblatt

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
603 KB
Volume
36
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Folate status of rheumatoid arthritis pa
Folate status of rheumatoid arthritis patients receiving long-term, low-dose methotrexate therapy
✍ Sarah L. Morgan; Joseph E. Baggott; Mary Altz-Smith 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 786 KB

The folate status of 29 healthy control subjects, 16 rheumatoid arthritis (RA) patients taking methotrexate (MTX), and 20 RA patients who were not being treated with MTX was estimated by an assay of the folate-dependent enzymatic synthesis of serine from formate and glycine, which is termed the C1 i

Bladder malignancy in a patient receivin
Bladder malignancy in a patient receiving low dose cyclophosphamide for treatment of rheumatoid arthritis
✍ Alan F. Ansher; John W. Melton III; Anthony J. Sliwinski 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB 👁 3 views

Cyclophosphamide treatment of malignant disease has been strongly associated with an increased incidence of bladder cancer. Recently there have been 3 papers reporting 4 cases of bladder cancer in patients treated with cyclophosphamide for benign disease (1-3). However, there is no increased inciden